Risankizumab Achieves Primary Endpoints over Ustekinumab in

Announced by AbbVie on October 15, 2023, positive results revealed 59% of patients treated with risankizumab and 40% of patients treated with ustekinumab achieved clinical remission, respectively.

Related Keywords

Laurent Peyrin Biroulet , Roopal Thakkar , Nancy University Hospital , Image Analysis Group Laurent Peyrin Biroulet , Infinity Institute , Image Analysis Group , United European Gastroenterology Week , Nancy University , Risankizumab , Bustekinumab , Clinical Remission , Clinical Response , Endoscopic Remission , Endoscopic Response , Cd , Crohn Disease , Crohn X27s Disease , Ibd , Inflammatory Bowel Disease , Skyrizi , Stelara ,